{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670320304611712.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.bmc.2013.01.074"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0968089613001247?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0968089613001247?httpAccept=text/plain"}}],"dc:title":[{"@value":"Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670320304611717","@type":"Researcher","foaf:name":[{"@value":"Naoki Miyamoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611716","@type":"Researcher","foaf:name":[{"@value":"Nozomu Sakai"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611724","@type":"Researcher","foaf:name":[{"@value":"Takaharu Hirayama"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611718","@type":"Researcher","foaf:name":[{"@value":"Kazuhiro Miwa"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611722","@type":"Researcher","foaf:name":[{"@value":"Yuya Oguro"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611721","@type":"Researcher","foaf:name":[{"@value":"Hideyuki Oki"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611714","@type":"Researcher","foaf:name":[{"@value":"Kengo Okada"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611723","@type":"Researcher","foaf:name":[{"@value":"Terufumi Takagi"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611715","@type":"Researcher","foaf:name":[{"@value":"Hidehisa Iwata"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611719","@type":"Researcher","foaf:name":[{"@value":"Yoshiko Awazu"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611713","@type":"Researcher","foaf:name":[{"@value":"Seiji Yamasaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611712","@type":"Researcher","foaf:name":[{"@value":"Toshiyuki Takeuchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611585","@type":"Researcher","foaf:name":[{"@value":"Hiroshi Miki"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611720","@type":"Researcher","foaf:name":[{"@value":"Akira Hori"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320304611584","@type":"Researcher","foaf:name":[{"@value":"Shinichi Imamura"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09680896"}],"prism:publicationName":[{"@value":"Bioorganic & Medicinal Chemistry"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2013-04","prism:volume":"21","prism:number":"8","prism:startingPage":"2333","prism:endingPage":"2345"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0968089613001247?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0968089613001247?httpAccept=text/plain"}],"createdAt":"2013-02-13","modifiedAt":"2025-10-19","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360290617897518208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension"}]},{"@id":"https://cir.nii.ac.jp/crid/1390859616450128896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Potential of TAK-593 Ophthalmic Emulsion for the Treatment of Age-Related Macular Degeneration"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.bmc.2013.01.074"},{"@type":"CROSSREF","@value":"10.1073/pnas.2023899118_references_DOI_4jNYVKW3VWvJH4R57t4I8kWO3O8"},{"@type":"CROSSREF","@value":"10.1248/bpb.b23-00066_references_DOI_4jNYVKW3VWvJH4R57t4I8kWO3O8"}]}